Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.
| Revenue (TTM) | $5.82B |
| Gross Profit (TTM) | $3.24B |
| EBITDA | $1.94B |
| Operating Margin | 41.90% |
| Return on Equity | 30.70% |
| Return on Assets | 16.80% |
| Revenue/Share (TTM) | $29.36 |
| Book Value | $31.57 |
| Price-to-Book | 3.84 |
| Price-to-Sales (TTM) | 4.30 |
| EV/Revenue | 3.412 |
| EV/EBITDA | 9.60 |
| Quarterly Earnings Growth (YoY) | 37.70% |
| Quarterly Revenue Growth (YoY) | 37.70% |
| Shares Outstanding | $202.70M |
| Float | $170.73M |
| % Insiders | 1.84% |
| % Institutions | 103.87% |
Volatility is currently contracting
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Regeneron (REGN) or Incyte (INCY). But which of these two stocks is more attractive to value investors?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Incyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the company to raise its 2026 revenue outlook.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Incyte NASDAQ: INCY reported second-quarter 2026 net product sales of $1.49 billion, up 40% from a year earlier, supported by demand growth across its marketed portfolio and a one-time non-cash benefit tied to the resolution of a CMS matter involving OPZELURA.
Incyte Corporation ends the first half of 2026 on a high note. Yesterday, its stock reached a 52-week high of $120.70. In my view, key drivers behind Incyte's recent rally are the promising efficacy of latarcibart in von Willebrand disease, along with strong performance from Opzelura and Zynyz.
Incyte (INCY) came out with quarterly earnings of $3.09 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $1.57 per share a year ago.
Drugmaker Incyte Corp reported on Tuesday higher second-quarter earnings and raised its annual revenue forecast after it settled a lawsuit with the U.S. government over Medicaid rebates tied to eczema cream Opzelura.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on INCY and any ticker you trade — then tracks every position and per-strategy win rate.
